1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Terumo Corporation

Terumo Corporation

4543.T
Terumo CorporationJP flagTokyo Stock Exchange
2,293.00
JPY
-31.00
- -
3.38TMarket Cap
Terumo Corporation
4543.T
(Tokyo Stock Exchange)

Recent

price

2,293.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
216.06
254.56
264.84
307.67
322.34
350.01
355.93
417.07
409.98
420.53
406.47
465.02
551.27
619.64
699.86
767.36
321.55
Revenue per Share
21.29
15.91
30.95
22.45
25.33
33.78
38.08
64.78
54.35
56.98
51.16
58.72
60.04
71.5
79.01
92.14
37.86
Basic EPS, GAAP
16.19
21.02
11.72
33.82
21.13
31.59
30.66
51.97
26.81
22.73
25.4
44.54
30.49
45.41
86.75
87.38
34.87
Free Cash Flow per Basic Share
4
4.37
5.5
6.37
7.25
8.8
10.05
11.24
13.37
13.71
14.01
15.51
18.75
21.52
24.06
27.99
11.02
Dividend per Share
251.25
191.26
216.71
232.78
252.41
279.71
382.33
445.36
468.43
497.82
538.87
585.61
613.63
667.72
712.49
783.16
699.7
Book Value per Share
203.23
53.81
93
126.06
159.05
147.35
13.78
75.22
156.77
196.18
254.82
328.95
385.02
496.63
556.07
529.55
515.91
Tangible Book Value per Share
1,519
1,519
1,519
1,519
1,519
1,500
1,445
1,409
1,462
1,495
1,510
1,512
1,488
1,488
1,481
1,475
1,487
Basic Weighted Avg Shares
328,214
386,686
402,294
467,359
489,506
525,026
514,164
587,775
599,481
628,897
613,842
703,303
820,209
921,863
1,036,171
1,131,877
477,989
Sales/Revenue/Turnover
19.08
16.3
13.23
13.97
13.78
15.56
17.07
18.47
17.79
17.59
16.03
16.49
14.31
15.2
15.22
15.58
15.4
Operating Margin (%)
20,392
28,835
32,553
39,881
40,692
44,674
34,471
42,035
44,035
52,358
53,932
58,882
70,238
76,745
85,449
95,379
39,957
Depreciation Expense
32,338
24,167
47,014
34,096
38,470
50,676
55,003
91,295
79,470
85,211
77,268
88,813
89,325
106,374
116,978
135,914
56,282
Net Income, GAAP
37.15
51.21
9.98
35.5
39.93
34.18
26.69
14.47
22.8
20.13
20.46
22.43
23.09
24.47
24.32
23.75
24.35
Effective Tax Rate (%)
9.85
6.25
11.69
7.3
7.86
9.65
10.7
15.53
13.26
13.55
12.59
12.63
10.89
11.54
11.29
12.01
11.77
Profit Margin (%)
157,664
98,870
171,111
150,049
282,511
205,911
80,797
232,029
255,810
248,762
312,600
380,992
393,395
342,964
482,531
320,309
448,155
Working Capital
636
130,999
159,151
117,068
219,652
159,343
210,335
288,776
225,135
195,870
218,497
224,875
220,714
74,978
159,838
99,910
159,804
LT Debt
335,456
352,537
437,909
496,245
573,523
511,544
491,522
550,435
698,112
754,882
856,662
1,012,313
1,111,063
1,327,090
1,368,535
1,584,509
1,313,508
Total Equity
11.35
6.85
8.14
6.49
5.42
6.9
8.14
10.65
8.97
9.08
7.3
7.55
6.89
7.17
7.57
7.54
3.67
Return on Invested Capital (%)
8.51
5.66
9.69
6.83
6.97
8.27
8.47
10.11
8.98
9.43
7.67
8.34
8.19
9.15
9.92
10.01
4.7
Return on Capital (%)
8.77
7.19
15.17
9.99
10.44
12.62
11.32
15.47
12.11
11.92
9.92
10.45
9.93
11.16
11.42
12.3
5.66
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
156,870
- -
15,000
LT Borrowings
74,978
- -
159,804
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,485
- -
1,484
Market Capitalization
4,063,056
3,946,245
4,013,589

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
722,116
- -
679,198
Cash, Cash Equivalents & STI
231,041
- -
195,263
Accounts Receivable, Net
178,710
- -
164,624
Inventories
286,599
- -
286,051
Total Current Liabilities
379,152
- -
231,043
Payables & Accruals
- -
- -
- -
ST Debt
156,870
- -
15,000
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.28%
13.25%
15.78%
Free Cash Flow
19.42%
36.47%
0.35%
Net Income, GAAP
12.02%
12.15%
16.19%
Sales/Revenue/Turnover
8.2%
13.04%
9.24%
Total Cash Common Dividend
12.23%
14.35%
15.91%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
215,252
228,621
239,077
238,912
921,863
2025
- -
- -
- -
- -
1,036,171
2026
- -
- -
- -
- -
1,131,877

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
15.14
18.49
20.03
- -
71.5
2025
- -
- -
- -
- -
79.01
2026
- -
- -
- -
- -
92.14

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10.36
0.14
10.98
- -
21.52
2025
- -
- -
- -
- -
24.06
2026
- -
- -
- -
- -
27.99
Similar Companies
PlexBio Co., Ltd. (6572.TWO)
Merit Medical Systems, Inc. (MMSI)
TINAVI Medical Technologies Co., Ltd. (688277.SS)
Supermax Corporation Berhad (7106.KL)
HOYA Corporation (HOCPF)
FluoGuide A/S (FLUO.ST)
Business
Terumo Corporation is a global medical technology company primarily engaged in the manufacturing and sale of medical devices and equipment. The company offers a comprehensive range of products including vascular intervention and cardio-surgical devices; infusion systems and disposable medical devices; blood management systems; and general hospital supplies. Its core product portfolio encompasses cardiovascular systems, blood transfusion systems, diabetes care products, and endovascular therapy devices. Terumo serves healthcare providers across multiple regions including Japan, Asia-Pacific, Europe, and the Americas. Founded in 1921 and headquartered in Tokyo, Japan, Terumo operates within the healthcare and medical technology industry, targeting hospitals, clinics, and healthcare professionals. Recent significant developments for Terumo Corporation include strategic partnerships and business expansions aimed at enhancing its product offerings and geographic footprint. In the last 1-2 years, Terumo has focused on advancing its vascular intervention and blood management technologies and expanding its presence in emerging markets. The company has introduced new products such as innovative catheter systems and enhanced blood transfusion equipment. Additionally, Terumo has engaged in acquisitions and collaborations to strengthen its portfolio, optimize its supply chain, and extend its capabilities in minimally invasive therapies and biotherapeutics. No major rebranding or name changes have been reported recently, keeping its established corporate identity intact. Operating through various subsidiaries, Terumo Corporation maintains a robust presence in the global medical devices market. Its strategic focus lies in cardiovascular and interventional systems, general hospital products, and blood management solutions. The company’s commitment to innovation is reflected in its ongoing development of advanced product lines and expansion into new healthcare markets worldwide. Terumo’s comprehensive product solutions serve diverse healthcare needs, including surgical procedures, chronic disease management, and emergency care, establishing it as a pivotal player in the medical technology segment.